Literature DB >> 18676324

Severe fatigue: could it be aplastic anemia?

Manuel G Afable1, Debra E Lyon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676324      PMCID: PMC4300140          DOI: 10.1188/08.CJON.569-573

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


× No keyword cloud information.
  20 in total

1.  Guidelines for the diagnosis and management of acquired aplastic anaemia.

Authors:  J C W Marsh; S E Ball; P Darbyshire; E C Gordon-Smith; A J Keidan; A Martin; S R McCann; J Mercieca; D Oscier; A W W Roques; J A L Yin
Journal:  Br J Haematol       Date:  2003-12       Impact factor: 6.998

Review 2.  The pathophysiology of acquired aplastic anemia.

Authors:  N S Young; J Maciejewski
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

Review 3.  Aplastic anaemia.

Authors:  N S Young
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

4.  Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.

Authors:  S Kojima; S Hibi; Y Kosaka; M Yamamoto; M Tsuchida; H Mugishima; K Sugita; H Yabe; A Ohara; I Tsukimoto
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

Review 5.  Current status of allogeneic bone marrow transplantation in acquired aplastic anemia.

Authors:  M M Horowitz
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

Review 6.  Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience.

Authors:  A Bacigalupo; R Brand; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

7.  Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil.

Authors:  Phillip Scheinberg; Olga Nunez; Colin Wu; Neal S Young
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

8.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.

Authors:  J Maciejewski; C Selleri; S Anderson; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

9.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

10.  Bone marrow graft in man after conditioning by antilymphocytic serum.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; J Choay; P Trolard; M Schneider; M Hayat; J R Schlumberger; C Jasmin
Journal:  Br Med J       Date:  1970-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.